Related Experiment Video
Updated: Jul 2, 2026
09:37
Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
Kawasaki disease in children.
1Bristol Royal Hospital for Children, Bristol, UK.
Heart (British Cardiac Society)
|August 14, 2008
Summary
Kawasaki disease (KD) is a childhood vasculitis affecting coronary arteries. Prompt treatment with immunoglobulin and aspirin significantly lowers severe cardiac complications in affected children.
Area of Science:
- Pediatric Cardiology
- Immunology
- Rheumatology
Background:
- Kawasaki disease (KD) is the leading cause of acquired heart disease in children.
- It involves acute, self-limiting systemic vasculitis with unknown origins.
- Coronary artery inflammation can lead to aneurysms, thrombosis, or sudden death.
Purpose of the Study:
- To provide a comprehensive review of Kawasaki disease.
- To discuss its history, diagnosis, epidemiology, and etiology.
- To explore immunopathogenesis, treatment strategies, and long-term cardiovascular outcomes.
Main Methods:
- Literature review of Kawasaki disease.
- Analysis of diagnostic challenges and epidemiological data.
- Synthesis of information on pathology, immunopathogenesis, and treatment.
Main Results:
- No specific diagnostic test exists for Kawasaki disease.
- Intravenous immunoglobulin and aspirin reduce cardiac complications from 25% to 4.7%.
- Myocardial and endothelial dysfunction can necessitate ongoing medical or surgical intervention.
Conclusions:
- Kawasaki disease requires prompt diagnosis and management to prevent severe cardiac sequelae.
- Understanding genetic influences and long-term cardiovascular effects is crucial.
- Emerging pharmacological treatments offer potential for improved management in children and adolescents.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:26Rocky Mountain Spotted Fever
Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...